Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Rohit Loomba, Jacob George, Laurent Castera, Sven Francque, Eric Lawitz, Ahsan Shoeb, Jesper Ole Clausen, Birgitte Andersen, Anna Bille Larsen, Lise Lotte Gluud

Open source

DOI: 10.1016/s2468-1253(26)00123-8
Published: 2026-09
Container: The Lancet Gastroenterology & Hepatology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2468-1253-26-00123-8,
  title = {Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial},
  author = {Rohit Loomba and Jacob George and Laurent Castera and Sven Francque and Eric Lawitz and Ahsan Shoeb and Jesper Ole Clausen and Birgitte Andersen and Anna Bille Larsen and Lise Lotte Gluud},
  year = {2026},
  journal = {The Lancet Gastroenterology \&amp; Hepatology},
  doi = {10.1016/s2468-1253(26)00123-8},
  url = {https://doi.org/10.1016/s2468-1253(26)00123-8}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial
AU  - Rohit Loomba
AU  - Jacob George
AU  - Laurent Castera
AU  - Sven Francque
AU  - Eric Lawitz
AU  - Ahsan Shoeb
AU  - Jesper Ole Clausen
AU  - Birgitte Andersen
AU  - Anna Bille Larsen
AU  - Lise Lotte Gluud
PY  - 2026
JO  - The Lancet Gastroenterology &amp; Hepatology
DO  - 10.1016/s2468-1253(26)00123-8
UR  - https://doi.org/10.1016/s2468-1253(26)00123-8
ER  -

APA

Loomba, R., George, J., Castera, L., Francque, S., Lawitz, E., Shoeb, A., Clausen, J. O., Andersen, B., Larsen, A. B., & Gluud, L. L. (2026). Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(26)00123-8

Source records

crossref · retrieved 2026-11-09T11:46:21.574Z